We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$121M
Cap. Flow
-$91.5M
Cap. Flow %
-33.22%
Top 10 Hldgs %
43.72%
Holding
87
New
14
Increased
18
Reduced
10
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$11.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.62M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.89M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$6.84M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$6.59M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.5M
2
BBIO icon
BridgeBio Pharma
BBIO
+$6.79M
3
XLRN
Acceleron Pharma
XLRN
+$6.08M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.72M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 75.01%
2 Financials 4.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
51
Iovance Biotherapeutics
IOVA
$2.24B
$382K 0.14%
20,000
-130,000
-87% -$2.86M
RCOR.WS
52
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$43K 0.02%
75,000
– –
MSACW
53
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$24K 0.01%
33,333
– –
ASND icon
54
Ascendis Pharma A/S
ASND
$16.5B
– –
-35,910
Closed -$5.72M
BFLY icon
55
Butterfly Network
BFLY
$1.75B
– –
-150,000
Closed -$1.57M
CRVS icon
56
Corvus Pharmaceuticals
CRVS
$1.19B
– –
-50,000
Closed -$242K
CTMX icon
57
CytomX Therapeutics
CTMX
$766M
– –
-125,000
Closed -$636K
EDIT icon
58
PUT
Editas Medicine
EDIT
$442M
– –
-100,000
Closed -$4.11M
FOLD
59
DELISTED
Amicus Therapeutics
FOLD
– –
-111,400
Closed -$1.06M
LKFT
60
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
– –
-20,000
Closed -$1.05M
IMVT icon
61
CALL
Immunovant
IMVT
$8.2B
– –
-30,000
Closed -$261K
IPHA
62
Innate Pharma
IPHA
$162M
– –
-125,000
Closed -$771K
KROS icon
63
Keros Therapeutics
KROS
$210M
– –
-12,500
Closed -$495K
LUNG icon
64
Pulmonx
LUNG
$57M
– –
-25,000
Closed -$900K
MREO
65
Mereo BioPharma
MREO
$48.7M
– –
-650,000
Closed -$1.57M
OCUL icon
66
Ocular Therapeutix
OCUL
$1.91B
– –
-750,000
Closed -$7.5M
PCVX icon
67
Vaxcyte
PCVX
$8.01B
– –
-50,000
Closed -$1.27M
SDGR icon
68
Schrodinger
SDGR
$1.12B
– –
-25,000
Closed -$1.37M
SPY icon
69
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
– –
-100,000
Closed -$42.9M
TNGX icon
70
Tango Therapeutics
TNGX
$4.48B
– –
-50,000
Closed -$647K
UTHR icon
71
United Therapeutics
UTHR
$22.5B
– –
-10,000
Closed -$1.85M
XBI icon
72
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-700,000
Closed -$88M
ZYME icon
73
Zymeworks
ZYME
$1.75B
– –
-38,814
Closed -$1.13M
ACHL
74
DELISTED
Achilles Therapeutics
ACHL
– –
-100,000
Closed -$779K
ASLN
75
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-6,250
Closed -$445K
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Affinity Asset Advisors held 87 positions worth $275M, down 30% from $396M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Affinity Asset Advisors withdrew a net $91.5M in Q4 2021, closing 32 positions and reducing 10 holdings. Its most notable exit was Ocular Therapeutix, an estimated $7.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Protagonist Therapeutics worth $8.25M.

  • Affinity Asset Advisors's largest Q4 2021 buy was Protagonist Therapeutics: 241,119 shares worth $8.25M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q4 2021, an estimated $11.4M increase.
  • Affinity Asset Advisors's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $6.79M.
  • Affinity Asset Advisors fully exited Ocular Therapeutix in Q4 2021, selling an estimated $7.5M.
  • Affinity Asset Advisors's ten largest holdings make up 44% of its $275M portfolio in Q4 2021.
  • Affinity Asset Advisors opened 14 new positions and closed 32 in Q4 2021.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $275M.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.